Homburger advises Biocorp on SK Capital’s investment in Swixx BioPharma

On December 15, 2025, Swixx BioPharma AG announced the signing of an agreement for a strategic investment by SK Capital Partners. The investment values Swixx BioPharma at more than EUR 1.5 bn. Swixx BioPharma is a leading global full-service partner in the distribution of biopharmaceutical products operating across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America.

Closing is expected in the second quarter of 2026, subject to customary regulatory approvals. After closing, SK Capital will become Swixx’s lead investor. Biocorp, together with the founders and other shareholders, including Mérieux Equity Partners and HBM Healthcare Investments, will reinvest alongside SK Capital.

Homburger is acting as counsel to Biocorp, the founders of Laboratorios Biopas, which was acquired by Swixx BioPharma in summer 2024 and, as part of that transaction, became shareholders in Swixx BioPharma. The Homburger team includes Andreas Müller, Claude Lambert, Hans Glent Abildgaard (all Corporate / M&A) and other subject matter specialists.